# Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)

> **NCT04804709** · PHASE1 · TERMINATED · sponsor: **Columbia University** · enrollment: 5 (actual)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma
- Diffuse Pontine and Thalamic Gliomas
- Diffuse Midline Glioma, H3 K27M-Mutant

## Interventions

- **DRUG:** Panobinostat 15 MG
- **DEVICE:** Focused Ultrasound with neuro-navigator-controlled sonication

## Key facts

- **NCT ID:** NCT04804709
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-28
- **Primary completion:** 2022-03-01
- **Final completion:** 2022-03-31
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** FDA withdrew approval of the new drug application (NDA) for panobinostat as of March 24, 2022 because it was not feasible for the company to complete the required postmarketing clinical trials.
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04804709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04804709, "Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG)". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04804709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*